BioSpace News Archive

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces its sponsorship of the Fall Clinical Dermatology Conference, being held October 20-23 in Las Vegas.

American Molecular Laboratories (AML), a state-of-the-art molecular diagnostic and biotech development company based in Chicago, Illinois, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.

GE Healthcare and Tribun Health have entered a collaboration with the intent to provide digital pathology departmental solutions that give healthcare providers a more holistic view of patient records.

Halberd Corporation (OTC Pink: HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria. The combined bacteria-antibody-nanoparticle cluster are then exposed to laser emissive energy. In lab testing, over 90% of each bacteria was eliminated in less than 20 minutes.

Axoft , a neurotechnology company, today launched and announced FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer.

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston.

Theranica Bio-electronics today announced positive top-line results in its double-blind, randomized, placebo-controlled, multi-center, pivotal clinical trial in the USA (NCT04828707).

Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD).

APCER Life Sciences, the preferred services provider for Pharmaceutical and Biotech companies looking for compliance solutions across the drug life cycle, has been awarded the ISO 9001:2015 Quality Management System certification.